Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
|
|
- Dwight Conley
- 6 years ago
- Views:
Transcription
1 The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases Department The Alfred Hospital This research project was funded by beyondblue
2 Final Report - A comprehensive report on whether the undertaking of the Project Services was in support of the Objectives and if not, why not - Appendix A; - A comparison between the achieved outcomes of the Project against the Objectives - Appendix A; - Where applicable, recommendations on how any Objectives that were not achieved could be achieved in the future: A study aim which was not met was to investigate neurocognitive performance in those who developed incident depression. This analysis was not performed as participant numbers were too low in the incident depression group (those who developed depression between baseline and follow-up, n = 10) for meaningful statistical analysis. For this Objective to be achieved in the future, a longer recruitment period would be required to allow for greater participant numbers. Also, an extended follow-up period would also benefit this Objective by allowing greater time periods for the development of incident depression. - Any statistics collected in the course of the Project - Appendix C. Conference Presentations and Publications Gibbie, T., Mijch, A., Ellen, S., Hoy, J., Hutchison, C., Wright, E., Chua, P. & Judd, F. (accepted). Depression and neurocognitive performance in individuals with HIV/AIDS: two year follow-up. HIV Medicine. Gibbie, T., Hay, M., Hutchison, C., & Mijch, A. (submitted). Depression, Social Isolation and Adherence to HAART We will present Depression, Social Isolation and Adherence to HAART at the 17 th Annual Conference of the Australasian Society for HIV Medicine (ASHM), Hobart, August 25 th with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 2 of 10
3 Appendix A Project Objectives 1. To examine the relationship between depression and quality of life, specifically whether depression is associated with increased at-risk behaviours, and whether depression is associated with poor adherence to treatment. 2. To examine the outcome of treatment (both HIV & depression) in individuals who are depressed by following them over time. 3. To determine the relative risk of developing neurocognitive defects and HIV dementia with and without incident depression or depressive symptoms. Achieved Outcomes In order to meet the Project Objectives, 80 HIV positive participants and 20 HIV negative participants were recruited for the follow-up phase of this study. Each participant completed a battery of questionnaires and neuropsychological tests. Each aim of the study and the Project Objectives has been successfully addressed and will be reported in turn: Depression in people living with HIV/AIDS and the associations of depression, HIV illness indicators, treatments and outcomes: At both baseline and follow-up there was a high rate of depressive symptoms with one third of the group scoring 14 or more on the Beck Depression Inventory (BDI). In the clinical interview (SCID), 27% of the group were found to have depression at baseline. On the whole, depression levels decreased between baseline and follow-up, with 14% of participants found to have depression diagnosed through clinical interview at follow-up (an average of two years later). There was no association between symptoms of depression and severity of HIV infection (such as CD4 cell counts, viral load and the duration of time since the diagnosis of HIV infection). In other words, those that had higher HIV viral loads or lower CD4 cell counts were not more likely to be depressed. Participants in close personal relationships had lower levels of depression than those who were not in a relationship. Similarly, people who were living alone reported significantly more symptoms of depression than those who lived with others. Higher levels of depression seemed to occur in those who were socially isolated and in poorer health. Depression in HIV positive participants and HIV negative controls and the relationship to increased at-risk behaviour. Research from the U.S.A, Europe and Australia has suggested men who have sex with men (msm) who use excessive drugs &/or alcohol are more likely to engage in at-risk sexual behaviour, increasing the likelihood of transmitting or contracting HIV and sexually transmitted infections (STI). The relationship between mental illness and at-risk behaviour is also under investigation, with early research suggesting increased high-risk sexual behaviour in people with mental illness. Many investigators have speculated on the links between depression and the spread of HIV infection. When depressed an individual may be less careful with regard to safe sex practice and risk behaviour. Depression and suicidality, often associated with indifference to health, may facilitate the extremely risky sexual behaviours and intravenous drug use practices reported by some of the most depressed subjects in surveys. with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 3 of 10
4 Objectives This analysis aimed to look for relationships between depression, drug and/or alcohol use and sexual risk behaviour in HIV positive msm. Method HIV positive participants (n = 80) completed questionnaires for depression (BDI), drug and alcohol use (frequency) and sexual risk behaviour (sex without a condom with a casual partner). Results Condom use with casual partners was not significantly correlated with depression scores or the amount of alcohol consumed on a weekly basis. However, illicit drug use was significantly correlated with unprotected anal sex with a casual partner (p <.05). Discussion These preliminary findings suggest HIV positive msm who use recreational illicit drugs are at-risk for HIV/STI transmission. Further investigation of these relationships is required to assess the nature of these relationships, which may then inform public health interventions. Depression in HIV positive participants and its relationship with poor adherence to Highly Active Antiretroviral Therapy (HAART). Estimates of the prevalence of depression in HIV-infected individuals range between 10% and 50%. Depression has been shown to have a negative impact on adherence to medication in chronic illness. Highly Active Antiretroviral Therapy (HAART) has resulted in a significant decline in HIV-related disease progression and mortality. To achieve the maximum benefit from HAART, patients must adhere to antiretroviral regimens for at least 95% of the time. These regimens are often complex and associated with significant sideeffects. Objectives The aim of this study was to investigate the prevalence of depression in HIV infected individuals compared to HIV negative controls and the association with depression and adherence to HAART. It was hypothesised that higher rates of depression would be found in people with HIV infection relative to controls, and that increased depression scores would be associated with reduced adherence to HAART. Method HIV positive (n = 80) and HIV negative (n = 20) participants were assessed for depression using the Beck Depression Inventory (BDI) and the Structured Clinical Interview for DSM-IV (SCID). Participants were identified as nonadherent if they reported less than 95% adherence to HAART (self-report). Results Overall, 14% of the HIV positive group met the criteria for SCID current mood disorder compared to 5% of controls. Similarly, 39% of HIV infected participants met the criteria for a past depressive episode compared to 15% of controls. HIV positive participants scored significantly higher on the BDI than controls (p <.05). Nonadherence to HAART was reported by 30.5% of those prescribed HAART. Multivariate analysis revealed that nonadherence to HAART was significantly associated with limited social support (living alone and not in a relationship) (p <.05) but not depression scores (p >.05). Discussion A higher prevalence of depression and past depressive episodes was identified in the group with HIV infection indicating the presence of compromised psychological health in people living with HIV infection. This study also found lower adherence to HAART in people living alone and not in a relationship. Health professionals should monitor and treat depression and should be particularly vigilant of adherence rates amongst those with limited social support. with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 4 of 10
5 To determine the relative risk of developing neurocognitive defects and HIV dementia with and without incident depression or depressive symptoms Objectives The aims of this study were to follow a cohort of HIV infected individuals for two years to: assess changes in depression and neuropsychological performance over time; explore the relationship between depression, HIV illness and neuropsychological performance; and to examine the natural history of Highly Active Antiretroviral Therapy (HAART) on depression and neurocognitive performance. Method HIV seropositive outpatients were assessed at baseline and at two-year follow-up. At each assessment patients were assessed for depression (using the Beck Depression Inventory (BDI) and Structured Clinical Interview (SCID-CV) and completed a battery of neuropsychological tests including the CANTAB and the Hopkins HIV Dementia Scale (HDS). Results Baseline results: 34.8% scored 14 on the BDI ( 14 suggests depressive symptoms (DS). The SCID-CV revealed 27% of participants met the criteria for current mood disorder. 7% of the participant s scores on the HDS indicated HIV associated cognitive changes. Follow-up results: 80 participants retested at two-year follow-up and were spilt into two groups based on BDI scores at baseline. CANTAB results revealed the cohort were significantly impaired on 9 of 10 measures compared with age-matched normative data. Neurocognitive performance significantly improved for participants with no DS at baseline, whereas participants with DS at baseline did not show as much improvement. Multivariate analysis revealed 40% of the change in cognitive performance was due to the variables age, AIDS and HAART regimens. Discussion These results suggest a significant decline in depression scores and an improvement in several neurocognitive domains overtime, with a relationship between HIV illness, HAART, symptoms of depression and neurocognitive performance. with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 5 of 10
6 Appendix C Statistics Table 1 HIV Illness Characteristics of HIV Seropositive Participants Variables HIV seropositive (n = 80) On HAART (%) 96% Mean time (years) HIV positive (SD) 13 (5) Previous AIDS diagnosis (%) 30% CD4 count cells/µl Median 522 Range th, 75 th percentile 311, 737 *HIV RNA viral load copies/ml Median 25 Range th, 75 th percentile 25, 2185 HIV RNA below detectability (%) 58% Note. * Undetectable viral load was calculated using the midpoint of the detectable limit of the assay (25 copies/ml). Table 2 Mean Depression Scores and Percent Diagnosed with Depression for HIV Seropositive (n = 80) and Seronegative Participants (n = 20) Variable HIV seropositive HIV seronegative BDI cognitive affective score Mean score (SD) 5.6 (5.3)* a 1.1 (2.5)* a SCID Depression Current (n) 14% (11) 5% (1) Lifetime (n) 39%* (31) 15%* (3) Note. *p < a Levene s test of equality of variance not assumed p < HIV seropositive participants had higher BDI scores and a greater prevalence of current and lifetime diagnoses of depression (Table 2). T-tests revealed that participants with HIV infection scored significantly higher (M = 5.6, SD = 5.3) than HIV negative controls (M = 1.1, SD = 2.5) on the BDI cognitive-affective items t(66) = 5.379, p =.000. There was no relationship between current depression diagnosis (SCID) and HIV status (χ 2 = 1.193, df = 1, p =.275). There was, however a significant difference between the groups on past depression (χ 2 = 4.159, df = 1, p =.041). with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 6 of 10
7 Intercorrelations between BDI cognitive affective scores and psychosocial variables were obtained for the HIV seropositive group. BDI scores correlated significantly with living situation (r =.31, p <.05) and relationship status (r =.27, p <.05). That is, increased BDI scores were significantly correlated with not being in a current relationship and living alone. Multiple regression analysis was undertaken to determine the independent influence of psychosocial factors and HIV illness on current diagnosis of depression for the HIV seropositive participants. Table 3 contains the results of this analysis. Using the enter method, the overall model was not significant for current depression (F 6,70 = 1.740, p > 0.05, adjusted R-squared =.059). Table 3 Multiple Linear Regression Analysis Predicting SCID Current Depression Diagnosis for HIV Seropositive Participants Current Depression Variable B SE t p HIV RNA CD4 cell count AIDS diagnosis Living situation Relationship status Note. N = 80. It can be seen in Table 3 that no variables included in this model significantly predicted depression. Adherence to medication. Responses to the interviews regarding recent medication adherence patterns indicated that 30.5% (n = 22) of participants on HAART had completely missed at least one antiretroviral dose in the previous 7 days. Scores on depression measures, living situation and relationship status were used to model the likelihood of adherence. Table 4 Logistic Regression Analysis Predicting Adherence to HAART Regimens Variable B Wald p Exp(B) BDI SCID current SCID lifetime Living situation Relationship status Note. N = 72. df = 1. with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 7 of 10
8 Depression and Neuropsychological Performance Table 5 Participant Neuropsychological Performance Compared to Age-matched Norms on the Grooved Pegboard and CANTAB at Baseline and Follow-up (z-scores). Depression Scores on the BDI and SCID at Baseline and Follow-up. Variable (domain) Baseline (n = 129) Follow-up (n = 78) Mean difference Std.Error 95% CI Mean difference Std.Error 95%CI from zero from zero Grooved Pegboard Psychomotor speed dominant hand * 0.09 (-1.50, -0.76) -0.47* 0.19 (-.85, 0.01) non-dominant hand * 0.18 (-1.48, -0.41) -0.35* 0.13 (-.62, 0.01) CANTAB -Mental flexibility * 0.16 (-1.50, -0.86) -0.54* 0.17 (-0.89, -.18) & attention (IED3) -Reaction Time (RTI1) -.709* 0.10 (-0.89, -0.49) 0.35* 0.00 (0.17, 0.52) (RTI2) -.654* 0.17 (-1.00, -0.33) -0.41* 0.14 (-0.68, -.13) -Spatial planning & problem (SOC1) 0.449* 0.08 (0.25, 0.59) (-0.26, 0.46) solving (SOC2) (-0.54, -0.04) (-0.13, 0.29) (SOC3) -.478* 0.09 (-0.71, -0.34) (-0.13, 0.27) -Spatial working memory (SWM1) -.601* 0.09 (-0.80, -0.42) -0.31* 0.11 (-.530,.007) (SWM2) -.507* 0.08 (-0.70, -0.37) -0.40* 0.12 (-0.65, -.15) Beck Depression Inventory mean(sd) 12.3(8.2) 10.1(7.9) > % 31% SCID - % current mood 27% (35/129) 14% (11/79) - % lifetime mood 26% (33/129) 39% (30/79) with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 8 of 10
9 Note. * Significantly (2-tailed) different from zero (p < 0.05) IED - measure of mental flexibility. RTI measure of psychomotor speed. SOC measure of problem solving and planning. SWM measure of spatial working memory SCID current mood diagnosis depressive symptoms within the past two weeks. SCID lifetime mood diagnosis past depressive episode, no symptoms within the past month. Table 4 Comparisons between Baseline Depressed and Not Depressed Groups on Neurocognitive Performance at Two Year Follow-up Depressed (n = 25) Not Depressed (n = 53) Mean change Std. Error 95% Mean change Std. Error 95% from BL of mean CI from BL of mean CI IED3a (-1.7, 0.05) 0.63* 1.74 (-0.98, -0.28) RTI1a 0.67* 0.26 (-1.2, -0.12) 0.96* 0.09 (-1.13, -0.77) RTI2a (-0.94, 0.43) (-0.96, -0.24) SOC1a (-0.16, 0.38) (-0.09, 0.84) SOC2a 0.28* 0.11 (-0.52, -0.04) 0.75* 0.21 (-1.18, -0.30) SOC3a 0.42* 0.16 (-0.76, -0.07) 0.55* 0.13 (-0.82, -0.27) SWM1a (-0.41, 0.32) 0.26* 0.11 (-0.49, -0.03) SWM2a (-0.39, 0.31) (-0.25, 0.22) Note. * Significant (2-tailed) change between baseline and follow-up (p <0.05). IED - measure of mental flexibility. RTI measure of psychomotor speed. SOC measure of problem solving and planning. SWM measure of spatial working memory with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 9 of 10
10 Table 5 Backward Elimination Regression Analysis examining Factors associated with changes in global neuropsychological performance scores over two years. Multivariate* FACTORS Coefficient Std. Error 95% Confidence Interval Lower Upper R-squared p-value Adjusted R-squared Age (years) Previous ADI No Yes On Lamivudine at BL CNS penetrating ART at follow-up No Yes On Stavudine at FU On Didanosine at FU On tenofovir at BL nevirapine at BL nevirapine at FU indinavir at BL abacavir at BL lopinavir at FU Note. Included in the model were treatment, illness and lifestyle variables. with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Page 10 of 10
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationAddressing Mental Health in HIV Prevention and Treatment Research Kathleen J. Sikkema, Ph.D.
Addressing Mental Health in HIV Prevention and Treatment Research Kathleen J. Sikkema, Ph.D. Professor of Psychology and Neuroscience, Global Health, and Psychiatry and Behavioral Sciences Director, Social
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV Endgame II: Stopping the Syndemics that Drive HIV
Sean B. Rourke, Ph.D., FCAHS Scientific and Executive Director, OHTN Professor of Psychiatry, University of Toronto Director, CIHR Centre for REACH 2.0 in HIV/AIDS Director, CIHR Collaborative Centre for
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationDOI: /hiv British HIV Association HIV Medicine (2014) ORIGINAL RESEARCH
DOI: 10.1111/hiv.12169 ORIGINAL RESEARCH Younger age, recent HIV diagnosis, no welfare support and no annual sexually transmissible infection screening are associated with nonuse of antiretroviral therapy
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationClinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States
Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States Linda Beer, PhD, Christine L. Mattson, PhD, Joseph Prejean, PhD, and Luke Shouse, MD 10 th International
More informationSecond generation HIV surveillance: Better data for decision making
Second generation HIV surveillance: Better data for decision making Prof Thomas M Rehle, MD, PhD Human Sciences Research Council, South Africa HAI Conference on Prevention and Control of the HIV Epidemic
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationPatient Care Planning Group April 3, 2014
Patient Care Planning Group April 3, 2014 Philip O. Toal, Ed.D,; LMHC, CET Administrator, Non-Residential Services The Center For Drug Free Living, a founding partner of Aspire Health Partners Participants
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationPatterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada.
Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada. Sophie Patterson 1,2, Wendy Zhang 1, Kate Salters 1, Yalin
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationReducing the HIV Burden: The PATH for Triples Intervention (PFT)
Reducing the HIV Burden: The PATH for Triples Intervention (PFT) Tania Calle SUMR Scholar 2018 Williams College Mentors: Donna Coviello, PhD, and Michael Blank, PhD Penn Center for AIDS Research Significance
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationPEP, PREP, HPTN052 and MLN2238
PEP, PREP, HPTN052 and MLN2238 Understanding the alphabet soup of HIV prevention and cure strategies Christina G Rivera, PharmD, BCPS Pharmacy Grand Rounds August 15, 2017 2017 MFMER slide-1 Presentation
More information11/8/2016. The Challenge of HIV Treatment
You Mean I Have to Talk About...Sex? Trudy Larson, MD Professor and Director, School of Community Health Sciences Medical Director, Nevada AIDS Education and Training Center Nat l HIV/AIDS Strategy Goals
More informationThe Past as Prologue: Emerging needs and future directions in research on HIV prevention and treatment among MSM
The Past as Prologue: Emerging needs and future directions in research on HIV prevention and treatment among MSM Ron Stall, PhD., M.P.H. Dept. of Behavioral and Community Heath Sciences Graduate School
More informationUnderstanding HIV/AIDS: The current state of the HIV epidemic in British Columbia Mark Gilbert, MD, MHSc, FRCPC
Understanding HIV/AIDS: The current state of the HIV epidemic in British Columbia Mark Gilbert, MD, MHSc, FRCPC STOP HIV/AIDS Provincial Expansion Knowledge Kick Off January 31, 2013 Learning objectives
More informationCascade of medical care to HIV-infected patients in Europe. Cristina Mussini
Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment
More informationHIV EPIDEMIC UPDATE: FACTS & FIGURES 2012
HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012 Number of Cases Note: In this surveillance report, HIV cases include persons reported with HIV infection (non-aids), advanced HIV (non-aids) and AIDS within a
More informationPractice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -
ASK SCREEN Test for HIV and STI Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically - Routinely obtain a thorough sexual history from all
More informationHigh rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
More informationAcknowledgements. Would you fly with this pilot/cabin crew (HIV) Dr Ewan Hutchison (UK) Dr Ries Simons (Netherlands) Dr Teresa Bassey (Nigeria)
Would you fly with this pilot/cabin crew (HIV) Dr Anthony Evans Chief, Aviation Medicine Section ICAO, Montreal Dr Claude Thibeault Medical Advisor IATA, Montreal Acknowledgements Dr Ewan Hutchison (UK)
More informationHousing / Lack of Housing and HIV Prevention and Care
Housing / Lack of Housing and HIV Prevention and Care Evidence and Explanations Angela A. Aidala, PhD Columbia University Mailman School of Public Health Center for Homeless Prevention Studies WOMEN AS
More informationAn evaluation of the STD profiles and safe sex practices of a sample of swingers
An evaluation of the STD profiles and safe sex practices of a sample of swingers Presented by: Edward M. Fernandes, Ph.D. Assistant Professor of Psychology Barton College, North Carolina George Gaither,
More informationNew Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016
New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 6 Table of Contents. Introduction.... Methodology... 3. Data Limitations.... Definitions used... 3 5. Overview of STBBI epidemiology
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationStatistics as a Tool. A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations.
Statistics as a Tool A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations. Descriptive Statistics Numerical facts or observations that are organized describe
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationEgocentric and sociocentric social network HIV sexual risk norms and behaviors among people who inject drugs and high-risk networks
Egocentric and sociocentric social network HIV sexual risk norms and behaviors among people who inject drugs and high-risk networks HPTN 037 Scholar: Diana M. Sheehan, PhD, MPH, Assistant Professor, Florida
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV LYNN KAKOS, PH.D. VA MARYLAND HEALTH CARE SYSTEM (VAMHCS) OBJECTIVES HIV in the VA Neurocognitive profile
More informationDevelopment of an HIV Risk Reduction Intervention for Older Seropositive African American Men
+ Development of an HIV Risk Reduction Intervention for Older Seropositive African American Men 2012 SUMR Symposium Mentor: Christopher Lance Coleman, PhD, MS, MPH, FAAN Spencer B. Stubbs Candidate for
More informationPatient s perceptions of switching from Atripla to Truvada and generic efavirenz
Patient s perceptions of switching from Atripla to Truvada and generic efavirenz Dr Hardeep Kang (ST4) Dr John Sweeney (Consultant) Background Atripla was approved as a fixed dose combination drug in 2006
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More information3 rd International Workshop on Women and HIV January 14 th, 2013
3 rd International Workshop on Women and HIV January 14 th, 2013 Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationPositive Psychosocial Factors & Antiretroviral Adherence among HIV-infected African Americans
Positive Psychosocial Factors & Antiretroviral Adherence among HIV-infected African Americans Shenell D. Evans, PhD HIV Center For Clinical And Behavioral Studies New York State Psychiatric Institute And
More informationGay Community Periodic Survey: Perth 2016
Gay Community Periodic Survey: Perth 06 Never Stand Still Art Social Sciences Centre for Social Research in Health Evelyn Lee Limin Mao Matt Creamer Sue Laing Jude Comfort Garrett Prestage Iryna Zablotska
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationModelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence
Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence Kate Mitchell, PhD Imperial College London London, UK 14 th June 2016 Introduction: HPTN 078 Enhancing
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationHPTN 061: The Brothers Study
HPTN 061: The Brothers Study PRESENTED BY: RISHA IRVIN, MD/MPH, FORMER HPTN SCHOLAR (SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH) AND CURRENT MEMBER OF THE JOHNS HOPKINS HPTN SITE ON BEHALF OF HPTN 061 Background
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationQ and A - the PARTNER Study: new results from PARTNER 2
Q and A - the PARTNER Study: new results from PARTNER 2 1. Study results What is the PARTNER Study? The PARTNER study is an international two-phase study that looked at whether HIV transmission occurs
More informationHIV Clinical Update- HIV prevention
HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months
More informationUnderstanding the spread of HIV among men who have sex with men in Belgium: results from online and on site special surveys
Understanding the spread of HIV among men who have sex with men in Belgium: results from online and on site special surveys Wim Vanden Berghe ITM HIV/AIDS center Department of Public Health Institute of
More informationNon-medical use of prescription drugs and sexual risk behaviors among depressed adolescents
Journal of Adolescent and Family Health Volume 9 Issue 1 Article 6 April 2018 Non-medical use of prescription drugs and sexual risk behaviors among depressed adolescents Michael S. Dunn Coastal Carolina
More informationHIV and the Buckeye State
HIV and the Buckeye State A Primer Karen Rubin, MPH Senior Community Engagement Coordinator rubin@ohioaidscoalition.org 614-340-6707 HIV 101 WHAT IS HIV? Human- can only infect humans Immunodeficiencyweakens
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationI M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep
I M ENDING HIV PrEP PATIENT INFORMATION endinghiv.org.au/prep THIS BOOKLET PROVIDES YOU WITH INFORMATION ABOUT Pre-Exposure Prophylaxis (PrEP) for HIV. CONTENTS 06 Who will benefit from PrEP? 04 What is
More informationAddressing mental health and psychosocial problems in the context of promoting MSM sexual health. Steven A. Safren, PhD
Addressing mental health and psychosocial problems in the context of promoting MSM sexual health Steven A. Safren, PhD MSM, Mental Health, and Sexual Health 1. Why address mental health in (sexual) health
More informationHIV Pre- Exposure Prophylaxis
HIV Pre- Exposure Prophylaxis KNOWLEDGE AND ATTITUDES IN NORTH QUEENSLAND GENERAL PRACTITIONERS Principle Investigator: William Lane Co-Supervisor 1: Professor Clare Heal Co-Supervisor 2: Dr Jennifer Banks
More informationAustralian Research Centre in Sex, Health & Society. EMBARGOED until am 4/8/09 Secondary Students and Sexual Health 2008
Australian Research Centre in Sex, Health & Society EMBARGOED until 10.30 am 4/8/09 Secondary Students and Sexual Health 2008 Melbourne, Australia Sample 2002 2008 Jurisdictions All All School sectors
More informationMANITOBA HIV REPORT 2015
MANITOBA HIV REPORT 2015 The Manitoba HIV Program provides information, specialized care, treatment, and support to approximately 1,250 people living with HIV across the province. The Program has two Winnipeg-based
More informationReceptive Anal Intercourse and HIV Infection
World Journal of AIDS, 2017, 7, 269-278 http://www.scirp.org/journal/wja ISSN Online: 2160-8822 ISSN Print: 2160-8814 Receptive Anal Intercourse and HIV Infection Gilbert R. Lavoie 1, John F. Fisher 2
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationPresented at International Violence, Abuse and Trauma Conference Dr. Priscilla Dass-Brailsford Georgetown University Washington DC
The Traumatic Lives of Women Living with HIV/AIDS Presented at International Violence, Abuse and Trauma Conference 9.8.2013 Dr. Priscilla Dass-Brailsford Georgetown University Washington DC Funded By Center
More informationUpdate Report # 45. Patterns of Sexual Behaviors and Sexual Risk among HIV Positive People in New York City
Update Report # 45 Patterns of Sexual Behaviors and Sexual Risk among HIV Positive People in New York City Angela A. Aidala Mary Ann Chiasson Gunjeong Lee Center for Applied Public Health Joseph L. Mailman
More informationManagement of Severe Primary HIV Infection
Management of Severe Primary HIV Infection Martin Fisher Brighton and Sussex University Hospitals Outline What is severe PHI? How frequent is severe PHI? Is this occurring more frequently? Is severe PHI
More informationNational guidelines for post-exposure prophylaxis after non-occupational exposure to HIV
National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV These guidelines outline the management of individuals who have been exposed (or suspect they have been exposed)
More informationHIV/AIDS Prevention Education As A Means of Prevention
HIV/AIDS Prevention Education As A Means of Prevention My name is Gustavo Alejos. I m a registered nurse which means that I have a Bachelor of Science Degree in Nursing. I am currently employed as a Nurse
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationAn update on Human Immuno Deficiency Virus/Acquired Immuno Deficiency Syndrome (HIV/AIDS)
An update on Human Immuno Deficiency Virus/Acquired Immuno Deficiency Syndrome (HIV/AIDS) (July 1, 2010) Ministry of Health Thimphu: Bhutan A. Background Total HIV cases as of December 1, 2009 185 Total
More informationSEXUAL ISSUES AFFECTING MEN IN LATER LIFE
HEALTH AND PSYCHOSOCIAL NEEDS OF OLDER GAY, BISEXUAL AND OTHER MEN WHO HAVE SEX WITH MEN Clinical Symposium: Providing Comprehensive Health Care to Men Who Have Sex with Men (MSM) New York City Department
More informationClinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org PRE-EXPOSURE PROPHYLAXIS Speaker: Antonia Urbina, MD 9/6/2017 Pre-Exposure Prophylaxis [video transcript] 1 00:00:07,480 --> 00:00:09,139 I mean we're
More informationCommunity oriented studies. New perspectives
Community oriented studies. New perspectives Swiss HIV Cohort Study Increased Viral Load Suppression in HIV+ Persons on ART Cohort size: 4624 4852 5045 5279 5556 5830 6121 6418 6526 100 Percent of individuals
More informationDetecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors? Jennifer Lewis, PsyD; Mathew Hirsch, PsyD & Susan Abramowitz, PhD NYU School of Medicine, New York, NY Friday,
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More information11/7/2012. HIV disease: Chronic Disease Patients are aging with their HIV disease on effective antiretroviral therapy (ART)
The Journey of HIV Infected Infected Patients Over 50: Implications for Nursing Care Objectives Julie Gumowski, RN, BSN Margaret Caplan, M.D. November 17, 2012 SAIC Frederick To discuss the prevalence
More informationPRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA
PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, 2015 9:00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS
More informationT here is a growing body of literature which suggests that
142 ORIGINAL ARTICLE Psychosocial predictors of HIV/STI risk behaviours in a sample of homosexual men A Beck, I McNally, J Petrak... See end of article for authors affiliations... Correspondence to: Dr
More informationHIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
More informationSeble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University
Seble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University November 5, 2016 None HIV epidemiology Global U.S. Washington, D.C.
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationPsychiatric Comorbidity in Depressed HIV Individuals: Common and Clinically Consequential
Psychiatric Comorbidity in Depressed HIV Individuals: Common and Clinically Consequential Bradley N. Gaynes, MD, MPH Professor of Psychiatry Associate Chair of Research Training and Education University
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationGynecology & Reproductive Health
Research Article Gynecology & Reproductive Health ISSN 2639-9342 Effects of Human Immunodeficiency Virus Infection and Antiretroviral Therapy on Ovarian Reserve and Invitro Fertilisation Success Mohamed
More informationPhaphama interventions to reduce both alcohol use and HIV/STI risks
Phaphama interventions to reduce both alcohol use and HIV/STI risks Presenter: Prof Leickness C. Simbayi, D.Phil. Executive Director, Social Aspects of HIV/AIDS and Health, Human Sciences Research Council,
More informationHIV Prevention Pearls
HIV Prevention Pearls Meghan Rothenberger, MD Assistant Professor Division of Infectious Diseases University of Minnesota Director, Youth and AIDS Projects October 27, 2017 Disclosure Information I have
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationHIV Epidemiology March 7, Stefanie Rhodes Inova Juniper Program
HIV Epidemiology March 7, 2019 Stefanie Rhodes Inova Juniper Program Stefanie.Rhodes@inova.org Human Immunodeficiency Virus Virus that attacks and weakens immune system Can be treated, but not cured Transmitted
More informationDay Seven: Helping HIV Affected Children and Orphans
Note: This training material is continually being evaluated and updated to reflect current needs and best practices therefore it should be viewed as work in progress. Any person, organization, or institution
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More information